NASDAQ:CLSNCelsion Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Celsion Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.93 +0.06 (+1.55 %) (As of 07/7/2020 12:43 PM ET) Add Compare Share Today's Range$3.76Now: $3.93▼$4.0650-Day Range$1.34MA: $3.39▼$5.2652-Week Range$0.69Now: $3.93▼$6.50Volume20,151 shsAverage Volume3.81 million shsMarket Capitalization$125.45 millionP/E RatioN/ADividend YieldN/ABeta2.48 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingCelsion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Celsion has a potential upside of 1.8% from its current price of $3.93.Amount of Analyst CoverageCelsion has only been the subject of 1 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesCelsion has received 380 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCelsion has received 302 “underperform” votes. (Add your “underperform” vote.)Community SentimentCelsion has received 55.72% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote “Outperform” if you believe CLSN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLSN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCelsion does not currently pay a dividend.Dividend GrowthCelsion does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celsion insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 20.49% of the stock of Celsion is held by insiders.Percentage Held by InstitutionsOnly 8.46% of the stock of Celsion is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Celsion are expected to decrease in the coming year, from ($0.65) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celsion is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celsion is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelsion has a P/B Ratio of 6.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.86 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLSN Previous Symbol CUSIPN/A CIK749647 Webwww.celsion.com Phone609-896-9100Debt Debt-to-Equity Ratio0.53 Current Ratio2.54 Quick Ratio2.54Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$500,000.00 Price / Sales250.89 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book6.24Profitability EPS (Most Recent Fiscal Year)($0.91) Net Income$-16,850,000.00 Net Margins-3,908.00% Return on Equity-120.14% Return on Assets-48.44%Miscellaneous Employees29 Outstanding Shares31,920,000Market Cap$125.45 million Next Earnings Date8/12/2020 (Estimated) OptionableOptionable NASDAQ:CLSN Rates by TradingView Receive CLSN News and Ratings via Email Sign-up to receive the latest news and ratings for CLSN and its competitors with MarketBeat's FREE daily newsletter. Celsion (NASDAQ:CLSN) Frequently Asked Questions How has Celsion's stock been impacted by COVID-19 (Coronavirus)? Celsion's stock was trading at $0.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CLSN stock has increased by 297.0% and is now trading at $3.93. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Celsion? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Celsion. When is Celsion's next earnings date? Celsion is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Celsion. How were Celsion's earnings last quarter? Celsion Co. (NASDAQ:CLSN) announced its quarterly earnings results on Friday, May, 15th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.03. The biotechnology company had revenue of $0.13 million for the quarter, compared to analysts' expectations of $0.13 million. Celsion had a negative return on equity of 120.14% and a negative net margin of 3,908.00%. View Celsion's earnings history. When did Celsion's stock split? How did Celsion's stock split work? Celsion's stock reverse split on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split. What price target have analysts set for CLSN? 2 equities research analysts have issued twelve-month price objectives for Celsion's shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Celsion's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 1.8% from the stock's current price. View analysts' price targets for Celsion. Has Celsion been receiving favorable news coverage? News articles about CLSN stock have been trending negative on Tuesday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Celsion earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Celsion. Who are some of Celsion's key competitors? Some companies that are related to Celsion include Neoleukin Therapeutics (NLTX), Legend Biotech (CALT), Urogen Pharma (URGN), Athersys (ATHX), Syndax Pharmaceuticals (SNDX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Clovis Oncology (CLVS), Flexion Therapeutics (FLXN), Protagonist Therapeutics (PTGX), Viking Therapeutics (VKTX), Emisphere Technologies (EMIS), Satsuma Pharmaceuticals (STSA), Beyondspring (BYSI) and Passage Bio (IMRA). View all competitors. What other stocks do shareholders of Celsion own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Amarin (AMRN), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY) and Novavax (NVAX). Who are Celsion's key executives? Celsion's management team includes the following people: Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 68)Mr. Jeffrey W. Church CPA, CPA, CFO, Exec. VP & Corp. Sec. (Age 62)Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 59)Dr. Nicholas Borys, Exec. VP & Chief Medical Officer (Age 60)Mr. Timothy J. Tumminello, Chief Accounting Officer & Controller (Age 61) What is Celsion's stock symbol? Celsion trades on the NASDAQ under the ticker symbol "CLSN." How do I buy shares of Celsion? Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Celsion's stock price today? One share of CLSN stock can currently be purchased for approximately $3.93. How big of a company is Celsion? Celsion has a market capitalization of $125.45 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-16,850,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Celsion employs 29 workers across the globe. What is Celsion's official website? The official website for Celsion is www.celsion.com. How can I contact Celsion? Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected] This page was last updated on 7/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
